Literature DB >> 17709742

HIV protease inhibitors and nuclear lamin processing: getting the right bells and whistles.

Steven Gerard Clarke1.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 17709742      PMCID： PMC1955769          DOI： 10.1073/pnas.0706529104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  20 in total

1.  Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.

Authors:  H C Côté; Z L Brumme; P R Harrigan
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

Review 2.  Zinc hydrolases: the mechanisms of zinc-dependent deacetylases.

Authors:  Marcy Hernick; Carol A Fierke
Journal:  Arch Biochem Biophys       Date:  2005-01-01       Impact factor: 4.013

Review 3.  Protease inhibitor-based regimens for HIV therapy: safety and efficacy.

Authors:  Sharon Walmsley
Journal:  J Acquir Immune Defic Syndr       Date:  2007-06-01       Impact factor: 3.731

Review 4.  Laminopathies: multisystem dystrophy syndromes.

Authors:  Katherine N Jacob; Abhimanyu Garg
Journal:  Mol Genet Metab       Date:  2005-12-20       Impact factor: 4.797

Review 5.  Prelamin A, Zmpste24, misshapen cell nuclei, and progeria--new evidence suggesting that protein farnesylation could be important for disease pathogenesis.

Authors:  Stephen G Young; Loren G Fong; Susan Michaelis
Journal:  J Lipid Res       Date:  2005-10-05       Impact factor: 5.922

6.  Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients.

Authors:  Joseph G Jemsek; Eduardo Arathoon; Massimo Arlotti; Carlos Perez; Nestor Sosa; Vadim Pokrovskiy; Alexandra Thiry; Michael Soccodato; Mustafa A Noor; Michael Giordano
Journal:  Clin Infect Dis       Date:  2005-12-05       Impact factor: 9.079

7.  Rational design of peptide-based HIV proteinase inhibitors.

Authors:  N A Roberts; J A Martin; D Kinchington; A V Broadhurst; J C Craig; I B Duncan; S A Galpin; B K Handa; J Kay; A Kröhn
Journal:  Science       Date:  1990-04-20       Impact factor: 47.728

8.  Prelamin A and lamin A appear to be dispensable in the nuclear lamina.

Authors:  Loren G Fong; Jennifer K Ng; Jan Lammerding; Timothy A Vickers; Margarita Meta; Nathan Coté; Bryant Gavino; Xin Qiao; Sandy Y Chang; Stephanie R Young; Shao H Yang; Colin L Stewart; Richard T Lee; C Frank Bennett; Martin O Bergo; Stephen G Young
Journal:  J Clin Invest       Date:  2006-03       Impact factor: 14.808

9.  Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation.

Authors:  Martine Caron; Martine Auclair; Hélène Sterlingot; Michel Kornprobst; Jacqueline Capeau
Journal:  AIDS       Date:  2003-11-21       Impact factor: 4.177

10.  Human lipodystrophies linked to mutations in A-type lamins and to HIV protease inhibitor therapy are both associated with prelamin A accumulation, oxidative stress and premature cellular senescence.

Authors:  M Caron; M Auclair; B Donadille; V Béréziat; B Guerci; M Laville; H Narbonne; C Bodemer; O Lascols; J Capeau; C Vigouroux
Journal:  Cell Death Differ       Date:  2007-07-06       Impact factor: 15.828
View more
  8 in total

Review 1.  Nuclear lamins: major factors in the structural organization and function of the nucleus and chromatin.

Authors:  Thomas Dechat; Katrin Pfleghaar; Kaushik Sengupta; Takeshi Shimi; Dale K Shumaker; Liliana Solimando; Robert D Goldman
Journal:  Genes Dev       Date:  2008-04-01       Impact factor: 11.361

2.  Probing cytoskeletal pre-stress and nuclear mechanics in endothelial cells with spatiotemporally controlled (de-)adhesion kinetics on micropatterned substrates.

Authors:  Marie Versaevel; Maryam Riaz; Tobias Corne; Thomas Grevesse; Joséphine Lantoine; Danahe Mohammed; Céline Bruyère; Laura Alaimo; Winnok H De Vos; Sylvain Gabriele
Journal:  Cell Adh Migr       Date:  2016-04-25       Impact factor: 3.405

Review 3.  HIV-associated lipodystrophy: impact of antiretroviral therapy.

Authors:  Giovanni Guaraldi; Chiara Stentarelli; Stefano Zona; Antonella Santoro
Journal:  Drugs       Date:  2013-09       Impact factor: 9.546

Review 4.  Biogenesis of the Saccharomyces cerevisiae pheromone a-factor, from yeast mating to human disease.

Authors:  Susan Michaelis; Jemima Barrowman
Journal:  Microbiol Mol Biol Rev       Date:  2012-09       Impact factor: 11.056

5.  The induction of a nucleoplasmic reticulum by prelamin A accumulation requires CTP:phosphocholine cytidylyltransferase-α.

Authors:  Chris N Goulbourne; Ashraf N Malhas; David J Vaux
Journal:  J Cell Sci       Date:  2012-01-05       Impact factor: 5.285

6.  A potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells.

Authors:  Catherine Coffinier; Sarah E Hudon; Roger Lee; Emily A Farber; Chika Nobumori; Jeffrey H Miner; Douglas A Andres; H Peter Spielmann; Christine A Hrycyna; Loren G Fong; Stephen G Young
Journal:  J Biol Chem       Date:  2008-01-28       Impact factor: 5.157

7.  Nelfinavir and nelfinavir analogs block site-2 protease cleavage to inhibit castration-resistant prostate cancer.

Authors:  Min Guan; Leila Su; Yate-Ching Yuan; Haiqing Li; Warren A Chow
Journal:  Sci Rep       Date:  2015-04-16       Impact factor: 4.379

Review 8.  The struggle of a good friend getting old: cellular senescence in viral responses and therapy.

Authors:  Jaskaren Kohli; Iris Veenstra; Marco Demaria
Journal:  EMBO Rep       Date:  2021-03-18       Impact factor: 8.807
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.